Which of the following statements are true regarding buprenorphine therapy and HCV? Choose one or more correct responses.
Buprenorphine does not cause elevated transaminases.
The dose of buprenorphine may have to be adjusted when direct anti-viral agents are administered.
There are no significant drug-drug interactions between buprenorphine and direct anti-viral agents.
.
Patients with impaired hepatic function can be treated with buprenorphine but should be monitored.
Question 2 of 3
SUBMI

There are no significant drug-drug interactions between buprenorphine and direct anti-viral agents.

Patients with impaired hepatic function can be treated with buprenorphine but should be monitored.

Buprenorphine does not cause elevated transaminases.

Explanation:

Buprenorphine is a medication used to treat severe pain, chronic pain and opioid use disorder. Buprenorphine is a partial agonist at the mu receptor, which binds to the mu-opioid receptor and activates it in order to produce a biological response. Examples of medications that interact with Buprenorphine include, among others, mixed opioid agonist-antagonists (i.e., butorphanol, pentazocine and nalbuphine), opiate antagonists (i.e., naltrexone), etc. Although patients with impaired hepatic function can be treated with this medication, it is important to highlight that they must be observed for reactions such as toxicity or overdose. Transaminases (also known as aminotransferases) are enzymes that catalyze the transfer of an amino group from an amine to an acceptor, and whose elevated levels in the blood can be an indicator of many diseases. The presence of elevated transaminases is associated with hepatic diseases such as nonalcoholic fatty liver diseases and alcoholic liver disease, which may be caused by drug-induced hepatotoxicity (i.e., ACE inhibitors, nicotinic acid, acetaminophen, erythromycin, antifungal agents, etc).

if you are asking how much they can go over the 1500 limit it would be safetly within the 2310 and 2600.mg